Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone
View Patent ↗A method of evaluating memory/learning functions with the use of a model with glutamic acid N-methyl-D-aspartate (NMDA) type receptor hypofunction as an animal model for schizophrenia and with the use of reference memory task, wherein there has been found concrete means for detecting any differences in activity between typical anti-psychosis drugs and atypical anti-psychosis drugs is found. An in vivo animal model for screening of a therapeutic agent for improving cognitive dysfunction by schizophrenia is provided.
1. A method for improving memory or learning dysfunctions caused by schizophrenia, comprising administering lurasidone, or an acid addition salt thereof, to a patient suffering from memory or learning dysfunctions caused by schizophrenia.
2. The method of claim 1 , in which the patient is administered a dose of from 0.3 to 10 mg/kg per os.
3. A method for improving memory or learning dysfunctions caused by schizophrenia, comprising administering lurasidone, or an acid addition salt thereof, to a patient suffering from memory or learning dysfunctions caused by schizophrenia, in which administering lurasidone induces neither memory dysfunction nor learning dysfunction.